- Home
- CCM vs TVGN Comparison
CCM vs TVGN Comparison
Compare CCM & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCM | TVGN |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 21.3M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCM | TVGN |
|---|---|---|
| Price | $4.96 | $6.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 66.4K | 8.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.14 |
| 52 Week High | $6.98 | $12.03 |
Technical Indicators
Market Signals| Indicator | CCM | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 58.32 |
| Support Level | $4.41 | $6.22 |
| Resistance Level | $5.42 | $7.42 |
| Average True Range (ATR) | 0.48 | 0.46 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 45.46 | 100.00 |
Price Performance
Historical ComparisonAbout CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.